




Written Report

Student name: DIE VALENTINE DJIHENAHU BA

Student ID: 2529381

Module code : LCHS4008

Module Title: Introduction to Public Health

lecturer name: Dr Patronella Ganza

Assignment title: Report on a Health Issue

Type 1 Diabetes

Introduction

Type 1 diabetes mellitus (T1D) is a chronic organ-specific autoimmune disease characterized by the selective destruction of insulin-producing pancreatic beta cells. Without endogenous insulin, affected individuals cannot transport systemic glucose into cell tissues for metabolic energy, resulting in persistent hyperglycemia. While typically diagnosed in childhood, onset occurs across the entire lifespan, requiring lifelong exogenous insulin. Classic clinical manifestations include polyuria, polydipsia, polyphagia, rapid unexplained weight loss, fatigue, blurry vision, delayed wound healing, and nocturnal enuresis. Unrecognized metabolic collapse may trigger diabetic ketoacidosis (DKA), an emergency characterized by systemic acidosis, nausea, abdominal pain, ketotic breath, and altered consciousness. Managing T1D in the community requires integrated, multi-disciplinary care, including Diabetes Specialist Nurses (DSNs), educational teams, continuous glucose monitoring (CGM), routine screening for secondary microvascular and macrovascular end-organ complications, targeted psychological interventions for diabetes distress, and dedicated social services for vulnerable populations (NICE, 2023a).

Main Body

Approaches to Measuring and Monitoring Type 1 Diabetes

Precision monitoring is the foundation of T1D management today, balancing the prevention of acute metabolic decompensation against long-term vascular protection.

Glycated Haemoglobin (HbA1c)

HbA1c is the most important retrospective marker of glycaemic control and reflects average blood glucose levels over the preceding 8 to 12 weeks. UK national guidance recommends a

target of HbA1c below 53 mmol/mol (7.0%) for most adults and children, provided this can be achieved without inducing severe hypoglycaemia (NICE, 2023a; NICE, 2023b). However, HbA1c has well-established clinical limitations: it does not capture day-to-day glycaemic variability and can yield misleading values in the presence of haemoglobinopathies, severe anaemia, or pregnancy.

Self-Monitoring of Blood Glucose (SMBG)

Capillary finger-prick testing is still a key backup and daily tool. UK patients using SMBG are advised to take 4 to 10 tests daily, usually before meals, before bed, before driving, ahead of physical exercise, and whenever acute hypo- or hyperglycaemia is suspected (NICE, 2023a).

Continuous Glucose Monitoring (CGM) & Advanced Metrics

The rapid clinical adoption of real-time (rtCGM) and intermittently scanned (isCGM/Flash) systems has transformed outpatient diabetes management. Integrated subcutaneous sensors track interstitial fluid glucose continuously and provide real-time glucose data, trend arrows, and threshold alarms to smartphones or dedicated readers. Key clinical targets established in consensus guidelines and endorsed across NHS practice include:

Time in Range (TIR, 3.9–10.0 mmol/L): Aim to reach 70% of readings for most people (Battelino et al., 2019).

Time Below Range (TBR, <3.9 mmol/L): Keep it under 4%, with severe hypoglycaemic exposure (<3.0 mmol/L) kept below 1%.

Time Above Range (TAR, >10.0 mmol/L): Keep below 25%.

Glycaemic Variability (%CV): The target coefficient of variation should be at or below 36% to signal stable and predictable glucose patterns.

When persistent hyperglycaemia or systemic illness occurs, point-of-care capillary or urinary ketone monitoring is essential to rule out evolving DKA. At a national level, surveillance registries such as the National Diabetes Audit (NDA) in England and Wales and the Scottish Diabetes Survey track care process completion, complication rates, and regional inequalities across the NHS ecosystem (NHS England, 2023; Scottish Diabetes Survey Monitoring Group, 2022).

Control Strategies and Management Pathways

Because there is currently no curative therapy for established T1D, control relies on precise exogenous insulin replacement, lifestyle optimization, structured self-management education, and technology.

Exogenous Insulin Delivery

Insulin regimens must mimic physiological secretion. Standard care involves either Multiple Daily Injections (MDI)—combining long-acting basal analogues with mealtime rapid-acting boluses guided by carbohydrate counting—or Continuous Subcutaneous Insulin Infusion (CSII) via insulin pumps.

Hybrid Closed-Loop (HCL) Systems

One of the most significant developments in NHS community care is Hybrid Closed-Loop (HCL) systems—often referred to as an 'artificial pancreas.' These technologies link CGM sensors directly to insulin pump algorithms to dynamically adjust basal delivery in real time. Following widespread clinical evidence demonstrating increased TIR and reduced hypoglycaemia burden, NICE approved a nationwide rollout of HCL technology across eligible NHS patients (Choudhary et al., 2023; NICE, 2023c).

Structured Education & Lifestyle Integration

Structured self-management education, such as the UK's Dose Adjustment For Normal Eating (DAFNE) program, is key. DAFNE equips patients with essential practical skills for flexible insulin titration, exercise management, sick-day rules, and hypoglycaemia treatment (DAFNE Study Group, 2002). Complementary lifestyle changes—including structured physical activity, smoking cessation, and cardiovascular risk reduction—remain central components of primary care routine health checks (Diabetes UK, 2023).

Community Impact, Complications, and Psychosocial Burden

The systemic impact of T1D reaches far beyond glycaemic metrics, affecting psychological well-being, social participation, and health economics across UK communities.

Physical Complications

- **Acute:** Severe hypoglycaemia (risking seizures, loss of consciousness, and trauma) and life-threatening DKA.
- **Microvascular:** Retinopathy (a leading cause of acquired visual impairment), nephropathy (potentially progressing to end-stage kidney disease requiring dialysis or transplantation), and peripheral neuropathy (increasing the risk of foot ulceration and lower-limb amputation).
- **Macrovascular:** Markedly elevated risk of premature ischemic heart disease, myocardial infarction, stroke, and peripheral vascular disease (NHS England, 2023).

Psychosocial and Caregiver Impact

Psychological morbidity in T1D is substantial. Diabetes distress—the emotional burden specifically linked to managing a demanding chronic condition—affects an estimated 20% to 40% of patients, while rates of clinical depression and anxiety are twice as high as those found in the general population (Speight et al., 2020). Fears of severe hypoglycaemia, body image concerns, and stigmatization frequently limit educational, social, and employment opportunities. Furthermore, informal caregivers (particularly parents of paediatric patients) experience severe sleep disruption, chronic anxiety, and caregiver burnout (Diabetes UK, 2023).

Health Economics and Inequalities

The operational cost of T1D to the NHS is immense, driven largely by emergency hospital admissions for avoidable acute crises and the long-term management of chronic vascular end-stage complications. These burdens are further multiplied by socio-economic disparities: epidemiological data continuously shows that patients living in socioeconomically deprived UK areas suffer significantly worse glycaemic outcomes, higher complication rates, and lower life expectancies compared to those in more affluent postcodes (NHS England, 2023).

Conclusion

Type 1 diabetes remains one of the most challenging and complex chronic health conditions in the UK. Managing this disease in the community is a multi-disciplinary, continuous clinical approach based on modern precision monitoring technologies, multidisciplinary education teams, and state-of-the-art automated technology. Exogenous insulin replacement, lifestyle



optimization, continuous glucose monitoring, and hybrid closed-loop systems have revolutionized self-management by preventing acute metabolic decompensation and protecting vascular health. These new medical techniques along with Diabetes Specialist Nurses and tailored psychological solutions alleviate the significant emotional burden of diabetes and the severe long-term microvascular and macrovascular disease consequences. In the end, the improvement of community care pathways, the reduction of emergency hospital admissions for preventable acute crises and tackling chronic socio-economic disparities in care delivery in the NHS ecosystem are the top priorities for public health policy in the UK.

References

Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., ... & Phillip, M. (2019). Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range. *Diabetes Care*, 42(8), 1593–1603. <https://doi.org/10.2337/dc19-0288>

Choudhary, P., Campbell, F., Leelarathna, L., Amiel, S. A., & UK HCL Clinical Group. (2023). Real-world implementation of hybrid closed-loop systems in NHS diabetes services: A UK national audit. *Diabetic Medicine*, 40(6), e15082. <https://doi.org/10.1111/dme.15082>

DAFNE Study Group. (2002). Training in flexible and intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose Adjustment For Normal Eating (DAFNE) randomised controlled trial. *BMJ*, 325(7367), 746–749. <https://doi.org/10.1136/bmj.325.7367.746>

Diabetes UK. (2023). Diabetes Statistics: Type 1 diabetes in the UK. Diabetes UK. <https://www.diabetes.org.uk>

National Institute for Health and Care Excellence (NICE). (2023a). Type 1 diabetes in adults: Diagnosis and management (NICE Guideline NG18). <https://www.nice.org.uk/guidance/ng18>

National Institute for Health and Care Excellence (NICE). (2023b). Type 1 and type 2 diabetes in children and young people: Diagnosis and management (NICE Guideline NG28). <https://www.nice.org.uk/guidance/ng28>

NHS England & Healthcare Quality Improvement Partnership (HQIP). (2023). National Diabetes Audit (NDA) 2021–2022: Core Report. NHS Digital. <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit>
